• PCN402 THE CLINICAL AND ECONOMIC CONSEQUENCES OF DELAYS IN REIMBURSEMENT FOR SELECT NOVEL CANCER THERAPEUTICS IN CANADA, ITALY, AND AUSTRALIA

    Nov 1, 2019, 00:00

  • PMH62 IMPROVEMENT IN FUNCTIONING, DEPRESSIVE AND COGNITIVE SYMPTOMS AFTER TREATMENT OF MAJOR DEPRESSION WITH VORTIOXETINE. INTERIM RESULTS FROM THE "REAL-LIFE EFFECTIVENESS OF VORTIOXETINE (RELIEVE)” STUDY

    Nov 1, 2019, 00:00

  • PCV13 INCIDENCE AND COST OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ACENOCOUMAROL, IN GREECE

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PIN21 THE ECONOMIC IMPACT OF TRICLOSAN-COATED SUTURES IN WOUND CLOSURE: A BUDGET IMPACT ANALYSIS FROM HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PNS357 HOW TO RESOLVE ISSUES EXPERIENCED BY PAYERS FOR THEIR INVOLVEMENT AT PRE-LAUNCH STAGE

    Nov 1, 2019, 00:00

  • PDG102 CLINICAL OUTCOMES COMPARING CLOPIDOGREL AND PRASUGREL/ TICAGRELOR IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PIH14 INCREMENTAL COSTS OF PREMATURITY AND LOW BIRTHWEIGHT

    Nov 1, 2019, 00:00

  • PRO110 A STRUCTURED REVIEW OF NICE AND SMC APPRAISALS IN ORPHAN GENETIC NEUROLOGICAL DISEASES: ECONOMIC AND CLINICAL UNCERTAINTIES AND HOW TO ADDRESS THEM

    Nov 1, 2019, 00:00

  • PIN63 COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE VERSUS VORICONAZOLE FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASE IN CHINA

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Nov 1, 2019, 00:00

  • ON6 IMPACT OF THE FOLLICULAR LYMPHOMA (FL) TREATMENT CONTINUUM ON A PATIENTS QUALITY OF LIFE (QOL) IN EUROPE (EU5)

    Nov 1, 2019, 00:00

  • PMU135 PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH CHRONIC OCULAR SURFACE PAIN : A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Multiple Diseases - Organizational Practices

    Nov 1, 2019, 00:00

  • PGI47 PSYCHOMETRIC VALIDATION OF THE INTESTINAL GAS QUESTIONNAIRE (IGQ) FOR MEASURING GAS RELATED SYMPTOMS AND THEIR IMPACT ON DAILY LIFE

    Nov 1, 2019, 00:00

  • PNS341 ANALYSIS OF EDUCATION AND TRAINING OPPORTUNITIES IN HE/PE/HTA IN CEE CONSORTIUM COUNTRIES

    Nov 1, 2019, 00:00

  • PRO58 CLINICAL AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN FRANCE: A RETROSPECTIVE ANALYSIS OF THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Nov 1, 2019, 00:00

  • PND32 COST-EFECTIVENESS AND BUDGET IMPACT OF VAGUS NERVE STIMULATION WITH ASPIRE SR MODEL 106 COMPARED TO ANTI-EPILEPTIC DRUGS IN A SUBGROUP OF PATIENTS WITH DRUG RESISTANT EPILEPSY IN PUBLIC SETTING IN TURKEY

    Nov 1, 2019, 00:00

  • PNS385 USING THE VARK MODEL TO AID QUALITATIVE DATA COLLECTION IN PEDIATRIC PATIENTS

    Nov 1, 2019, 00:00

  • PCN237 IMPACT OF ORAL TARGETED THERAPY ON THE ECONOMIC BURDEN OF CLL IN CANADA

    Nov 1, 2019, 00:00

  • PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB

    Nov 1, 2019, 00:00

  • PCN517 VARIABILITY OF COST TRAJECTORIES OVER THE LAST YEAR OF LIFE; AN EXPLORATIVE STUDY IN PATIENTS WITH ADVANCED BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PNS106 FACTORS AFFECTING THE HEALTHCARE PROVIDERS KNOWLEDGE OF PROJECT MANAGEMENT

    Nov 1, 2019, 00:00

  • PMS44 FRACTURES OF THE RADIUS IN WOMEN AGED 50 YEARS AND OVER: A STUDY OF ELECTRONIC MEDICAL RECORDS

    Nov 1, 2019, 00:00

  • PRO19 THE ROLE PLAYED BY SOCIAL COSTS IN ECONOMIC EVALUATIONS OF RARE DISEASE INTERVENTIONS

    Nov 1, 2019, 00:00

  • PNS318 NETWORK META-ANALYSES COMBINING RANDOMIZED AND NON-RANDOMIZED EVIDENCE; A NICE HTA REVIEW

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS390 EMA/FDA PARALLEL QUALIFICATION PROCEDURE FOR THE DEVELOPMENT OF NOVEL PATIENT REPORTED OUTCOME INSTRUMENTS:PROCESS AND IMPACT

    Nov 1, 2019, 00:00

  • PIH60 PEDIATRIC PATIENT ENGAGEMENT: USING PATIENT INSIGHTS TO IMPROVE STUDY DESIGN

    Nov 1, 2019, 00:00

  • PCV107 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENT IN PATIENTS WITH HYPERTENSION IN HONG KONG (HK) SAR,CHINA

    Nov 1, 2019, 00:00

  • PMD21 ECONOMIC EVALUATION OF THE SFLT-1/PLGF RATIO TEST TO GUIDE THE MANAGEMENT OF CHINESE SUSPECTED PRE-ECLAMPSIA WOMEN

    Nov 1, 2019, 00:00

  • PIN99 INDIRECT COSTS ASSOCIATED WITH SKIN AND SOFT TISSUE INFECTIONS IN CHILDREN: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMH54 IS THE OXCAP-MH CAPABILITY MEASURE A FEASIBLE AND PSYCHOMETRICALLY VALID TOOL FOR THE ROUTINE EVALUATION OF MENTAL HEALTH SERVICES?

    Nov 1, 2019, 00:00

  • Drugs Generics - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV48 COST EFFECTIVENESS OF RIVAROXABAN IN CORONARY ARTERY DISEASE AND/OR PERIPHERAL ARTERY DISEASE FOR 5 DIFFEREN PATIENT SUB-GROUPS IN TURKEY

    Nov 1, 2019, 00:00

  • PNS232 HTA RESHAPING: REDEFINING THE HEALTH TECHNOLOGY EVALUATION FRAMEWORK IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • PDG8 SYNCHRONISING MARKET AND BRAND SHAPING ACTIVITIES: THE IMPORTANCE OF POLICY AND BRAND ALIGNMENT

    Nov 1, 2019, 00:00

  • PND131 HOW WELL ARE MULTIPLE SCLEROSIS PATIENTS INFORMED ABOUT THEIR DISEASE AND THEIR TREATMENT: AN ANALYSIS OF DATA COLLECTED BY A NOVEL MOBILE APPLICATION (MS GEMEINSAM)

    Nov 1, 2019, 00:00

  • PDB46 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): PRODUCTIVITY LOSS AND INDIRECT COSTS

    Nov 1, 2019, 00:00

  • PIH24 COST-UTILITY ANALYSIS OF NEWBORN SCREENING PROGRAM BY TANDEM MASS SPECTROMETRY IN JAPAN

    Nov 1, 2019, 00:00

  • PND107 NEUROLOGIST AND PATIENT PREFERENCES IN MULTIPLE SCLEROSIS: UK AND US QUALITATIVE RESEARCH FINDINGS

    Nov 1, 2019, 00:00

  • PIN37 HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN CHILDREN IN THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS31 REIMBURSEMENT IN GERMANY: THE IMPACT OF G-BA RECENTLY REVISED REQUIREMENTS FOR AMNOG DOSSIERS

    Nov 1, 2019, 00:00

  • PMU116 NICE MEDICAL TECHNOLOGIES GUIDANCE: IMPACT BEYOND THE UK

    Nov 1, 2019, 00:00

  • PCN294 THE IMPACT OF VALUE-BASED CARE ON ONCOLOGY SPECIALTY PHYSICIANS

    Nov 1, 2019, 00:00

  • PNS155 ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES

    Nov 1, 2019, 00:00

  • PRO145 THE HUMANISTIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMS4 EFFICACY OF RENAL FUNCTION IN PATIENTS WITH EARLY DIABETIC NEPHROPATHY COMPLICATED WITH HYPERURICEMIA.

    Nov 1, 2019, 00:00

  • PNS25 EVALUATION OF THE SCIENTIFIC ACTIVITY OF MEDICAL UNIVERSITIES AND RESEARCH CENTERS TO CREATE THE NATIONAL STRATEGY OF THE MEDICAL SCIENCE DEVELOPMENT

    Nov 1, 2019, 00:00

  • PMS10 COMPARATIVE ANALYSIS OF HIP PROSTHESIS BY REVISION METHODS FOR LATERAL AND DIRECT ANTERIOR APPROACH

    Nov 1, 2019, 00:00

  • PNS375 FEASIBILITY OF AN ONLINE-ONLY METHOD OF GENERATING SUBJECT USABILITY AND COGNITIVE UNDERSTANDING DATA FOR ELECTRONICALLY ADMINISTERED QUESTIONNAIRES: AN EXAMPLE USING THE TREATMENT SATISFACTIONS QUESTIONNAIRE FOR MEDICATION (TSQM)

    Nov 1, 2019, 00:00

  • PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN

    Nov 1, 2019, 00:00

  • PCN267 PREVALENCE OF DIFFERENT TYPES OF CANCER IN GERMANY: A COMPARATIVE ANALYSIS OF CLAIMS DATA AND REGISTRY DATA IN GERMANY

    Nov 1, 2019, 00:00

  • PDG45 5 YEAR STATUS OF RISK SHARING AGREEMENT IN KOREA SINCE THE IMPLEMENTATION

    Nov 1, 2019, 00:00

  • PIN45 A COST-UTILITY ANALYSIS OF SEASONAL QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINE IN TURKEY

    Nov 1, 2019, 00:00

  • PIH4 SUPPORTING THE CONTENT VALIDITY OF THE MENSTRUAL PICTOGRAM SUPER-ABSORBENT POLYMERS CONTAINING VERSION 3 (MP SAP-C V3) USING DATA FROM COGNITIVE INTERVIEWS (CIS) OF WOMEN WITH UTERINE FIBROIDS (UF)

    Nov 1, 2019, 00:00

  • PSU9 COSTS OF STOMA MANAGEMENT POST COLORECTAL SURGERY IN THE UK HEALTHCARE SYSTEM AND IMPLICATIONS OF POTENTIAL REDUCTION IN NEED FOR OSTOMY PLACEMENT

    Nov 1, 2019, 00:00

  • Cancer - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG108 CLINICAL OUTCOMES ON SWITCHING BETWEEN NEWER P2Y12 RECEPTOR INHIBITORS AND CLOPIDOGREL IN DUAL ANTIPLATELET THERAPY IN HONG KONG ACUTE CORONARY SYNDROME POPULATION USING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PRS42 THE ASSOCIATION OF ACUTE RESPIRATORY INFECTIONS WITH METEOROLOGICAL FACTORS AND AIR POLLUTANTS AMONG CHILDREN IN MACAO: A RETROSPECTIVE ANALYSIS BASED ON ARDL APPROACH

    Nov 1, 2019, 00:00

  • PCV8 EFFICACY OF VENOUS EXERCISE FOR THE CHANGE OF VENOUS FLOW VELOCITY AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • Cancer - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN347 COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE

    Nov 1, 2019, 00:00

  • PIH5 USING ARTIFICIAL REPRODUCTIVE DATABASE TO ESTABLISH PREDICTED PROBABILISTIC MODEL OF A SUCCESS LIVE BIRTH AFTER IN VITRO FERTILIZATION

    Nov 1, 2019, 00:00

  • PRO62 SYSTEMATIC LITERATURE REVIEW OF DISEASE BURDEN, COSTS AND MODELS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

    Nov 1, 2019, 00:00

  • PNS119 PHARMACEUTICAL POLICY REFORM UNDER SOCIAL HEALTH INSURANCE IN INDONESIA: DOES ACCESS TO QUALIFIED MEDICINE GET BETTER?

    Nov 1, 2019, 00:00

  • PCN70 EVALUATING AN ONLINE CALCULATOR FOR ANALYZING DRUG COSTS OF THERAPY OF METASTATIC BREAST CANCER IN RUSSIAN FEDERATION: A NATIONAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB77 WILSON'S DISEASE: COST OF HOSPITALIZATION IN GERMANY

    Nov 1, 2019, 00:00

  • PDB128 A NATIONWIDE, OBSERVATIONAL STUDY ASSESSING ADHERENCE TO THE HELLENIC GUIDELINES FOR FOLLOW-UP, CLINICAL, AND LABORATORY EVALUATIONS, IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE GLANCE™ STUDY

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS203 USE OF DISCRETE CHOICE EXPERIMENTS TO INFORM HTA DECISION MAKING.

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PMH57 IMPACT ON QUALITY OF LIFE AND PRODUCTIVITY FOR CAREGIVERS OF ADULTS WITH DEPRESSION

    Nov 1, 2019, 00:00

  • PAM3 INDIVIDUALIZED NUTRITIONAL SUPPORT IN MEDICAL INPATIENTS RESULTS IN COST SAVINGS: ECONOMIC EVALUATION OF THE EFFORT TRIAL

    Nov 1, 2019, 00:00

  • PIT3 PROGNOSTIC FACTORS FOR POOR RECOVERY AFTER TRAUMA: A PROSPECTIVE MULTICENTRE COHORT STUDY

    Nov 1, 2019, 00:00

  • PND56 BUDGET IMPACT ANALYSIS OF INCLUSION IN THE PUBLIC FINANCING OCRELIZUMAB THERAPY FOR PRIMARY-PROGREDIENT AND HIGHLY ACTIVE REMITTING FORMS OF MULTIPLE SCELEROSIS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PDG4 TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON

    Nov 1, 2019, 00:00

  • PCN518 ONCOLOGY REAL WORLD DATA (RWD): ENABLING LEARNING HEALTH SYSTEMS

    Nov 1, 2019, 00:00

  • PIN152 ECONOMIC IMPACT OF SEQUELAE RELATED TO INVASIVE MENINGOCOCCAL DISEASE IN A FRENCH REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PCN450 FITTING A MIXTURE MODEL OF CANCER EXCESS MORTALITY RATES WITH A TRANSFORMATION STEP, TO CANCER RELATIVE SURVIVAL DATA.

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCV135 OBSERVATIONAL, INTERNATIONAL, COHORT STUDY TO EVALUATE THE SATISFACTION AND PREFERENCES OF PATIENTS IN PREVENTIVE TREATMENT OF SECONDARY CARDIOVASCULAR EVENTS WITH A CARDIOVASCULAR POLYPILL

    Nov 1, 2019, 00:00

  • PCN19 RELATIONSHIP OF STATIN OR ANTI PLATELET AGENTS AND HEPATOCELLULAR CARCINOMA IN TREATMENT NAIVE PATIENTS WITH CHB

    Nov 1, 2019, 00:00

  • ND4 WHO BENEFITS MOST FROM COLLABORATIVE DEMENTIA CARE? A POST-HOC SUBGROUP COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PIN27 ECONOMIC AND QUALITY OF LIFE BURDEN OF PAEDIATRIC INFLUENZA IN AUSTRALIA

    Nov 1, 2019, 00:00

  • PCN519 REAL WORLD EVIDENCE (RWE): ANALYSIS OF THE PROGNOSIS OF PATIENTS WITH METASTATIC COLON CANCER UNDER BIOLOGIC TREATMENT IN THE SOCIAL SECURITY SECTOR OF ARGENTINA

    Nov 1, 2019, 00:00

  • PMU112 ADHERENCE: NUDGING INNOVATION OF OUTCOMES-BASED CONTRACTS TO REWARD BEHAVIOR

    Nov 1, 2019, 00:00

  • PBI78 CAR-T TREATMENTS: INSIGHTS FROM INITIAL HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN THE UK, GERMANY AND FRANCE

    Nov 1, 2019, 00:00

  • PDG71 A STUDY OF PHARMACIST'S LEVEL OF AWARENESS ABOUT FIRST REIMBURSEMENT PROGRAM IN UKRAINE

    Nov 1, 2019, 00:00

  • PDB14 COST-EFFECTIVENESS OF CONTRAVE® IN OBESITY MANAGEMENT IN CANADA

    Nov 1, 2019, 00:00

  • PMU27 BUDGET IMPACT ANALYSIS OF IMPLEMENTING THE CLOSED-SYSTEM TRANSFER DEVICE QIMONO® DURING CHEMOTHERAPY ADMINISTRATION IN A FRENCH HOSPITAL

    Nov 1, 2019, 00:00

  • PNS166 WHICH FACTORS INFLUENCE PRICING DECISION WHEN A NEW INDICATION ARRIVES?

    Nov 1, 2019, 00:00

  • PCN390 ANALYSIS OF INDIRECT TREATMENT COMPARISONS IN ONCOLOGY-RELATED HTA DECISIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PMS71 THE BURDEN OF CONTROLLED AND UNCONTROLLED GOUT: AN ANALYSIS OF PATIENT-REPORTED OUTCOMES IN THE EUROPEAN UNION FIVE (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM)

    Nov 1, 2019, 00:00

  • PIN106 SYSTEMATIC LITERATURE REVIEW OF HERPES ZOSTER INCIDENCE WORLDWIDE

    Nov 1, 2019, 00:00

  • PCN272 OBINUTUZUMAB TREATMENT ON 1ST LINE HIGH AND INTERMEDIATE RISK FOLLICULAR LYMPHOMA. SHORT-TERM REDUCTION OF RELAPSED OR REFRACTORY DIRECT MEDICAL COSTS IN ARGENTINA AND CHILE.

    Nov 1, 2019, 00:00

  • Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions

    Nov 1, 2019, 00:00

  • PMH44 INCREASED USE OF AUGMENTATION THERAPIES ILLUSTRATES COMPLEX MANAGEMENT OF TREATMENT RESISTANT DEPRESSION. PRELIMINARY RESULTS FROM A REAL-WORD EVIDENCE REGISTRY IN EUROPE, THE 54135419DEP4001 STUDY

    Nov 1, 2019, 00:00

  • PND25 SYSTEMATIC LITERATURE REVIEW OF ECONOMIC BURDEN ASSOCIATED WITH MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PND126 ANTI-DEMENTIA DRUGS: CHANGING PRESCRIBING PATTERNS WITH THE INTRODUCTION OF GENERIC DRUGS

    Nov 1, 2019, 00:00

  • PDG19 CHARACTERISTICS AND HEALTHCARE SERVICE USE OF PATIENTS WITH SCHIZOPHRENIA SWITCHING FROM ORAL TO LONG-ACTING INJECTABLE ANTIPSYCHOTICS

    Nov 1, 2019, 00:00

  • PDG64 TRENDS IN THE USE OF LIPID-LOWERING DRUGS IN IVORY COAST (2017-2018)

    Nov 1, 2019, 00:00

  • PIN93 REAL WORLD DATA EXAMINING THE EFFECT OF DIRECT ACTING ANTIVIRALS AMONG PATIENTS DEFINED BY FIBROSIS STAGE AND VIRAL LOAD

    Nov 1, 2019, 00:00

  • PGI13 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS379 SUFFERING ALONE: UNMET NEEDS FOR INFORMAL CARE IN HUNGARY, POLAND AND SLOVENIA

    Nov 1, 2019, 00:00

  • PMU145 SYSTEMATIC REVIEW OF PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: DONOR AVAILABILITY, QUALITY OF LIFE AND ECONOMIC IMPLICATIONS

    Nov 1, 2019, 00:00

  • PMH39 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED INSOMNIA BY INSOMNIA SYMPTOMS: 2018 NATIONAL SLEEP SURVEY

    Nov 1, 2019, 00:00

  • PNS124 FRAMEWORK CONCEPTS FOR FINANCIAL RISK SHARING IN NOVEL POTENTIALLY CURATIVE MODALITIES

    Nov 1, 2019, 00:00

  • PRO61 EPIDEMIOLOGY OF HEMOPHILIA IN GERMANY: RESULTS FROM A GERMAN STATUTORY HEALTH INSURANCE CLAIMS DATABASE-ANALYSIS

    Nov 1, 2019, 00:00

  • PND89 NEGATIVE HTA RECOMMENDATIONS FOR MEDICINES IN NEUROLOGY THERAPEUTIC AREAS – FOURFOLD HIGHER ODDS IN POLAND COMPARED WITH THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PSY35 A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS EVALUATING RECENTLY APPROVED BIOLOGICAL THERAPIES FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN THE US, CANADA AND UK

    Nov 1, 2019, 00:00

  • PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN

    Nov 1, 2019, 00:00

  • RW4 APPLICATION OF ARTIFICIAL INTELLIGENCE AND MEDICAL BIG-DATA IN REAL WORLD EVIDENCE GENERATION: A LITERATURE REVIEW OF RESEARCH PRACTICE IN CHINA

    Nov 1, 2019, 00:00

  • PCN432 EVALUATION OF MISSING DATA IMPUTATION STRATEGIES IN CLINICAL TRIAL AND EMR DATA USING STANDARDIZED DATA MODELS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Organizational Practices

    Nov 1, 2019, 00:00

  • Individual's Health - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PSS9 DRUG UTILIZATION AND COSTS OF INTRAVITREAL INJECTED ANTIVEGFS IN ITALY

    Nov 1, 2019, 00:00

  • PDG87 ARE VALUE ASSESSMENT FRAMEWORKS USING RWE? A REVIEW OF NICE AND ICER PSORIASIS ASSESSMENTS

    Nov 1, 2019, 00:00

  • PND87 SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES (HSUVS) IN MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PSU4 COMPARISON OF OBESITY CLASSIFICATIONS AT 1, 3, AND 5 YEARS AFTER GASTRIC BYPASS AND GASTRIC SLEEVE SURGERY USING A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK

    Nov 1, 2019, 00:00

  • PCN33 ADJUSTED COMPARISON OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS LENALIDOMIDE PLUS DEXAMETHASONE (RD) IN SECOND LINE (2L) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS, USING INDIVIDUAL PATIENT LEVEL DATA (IPD) ...

    Nov 1, 2019, 00:00

  • PSS6 WHAT IS THE LIFETIME COST OF BLINDNESS IN PEOPLE WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY IN THE UK?

    Nov 1, 2019, 00:00

  • PDB91 AN MCDA APPROACH IN THE EVALUATION OF NEW TECHNOLOGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT

    Nov 1, 2019, 00:00

  • PCN125 IMPACT OF PALLIATIVE CARE CONSULT SERVICES ON THE COST OF CARE IN HUNGARY

    Nov 1, 2019, 00:00

  • Methodological and Conceptual Studies

    Nov 1, 2019, 00:00

  • PBI70 WILL CAR-T CELL THERAPIES CHANGE HOW DRUGS ARE PRICED AND REIMBURSED?

    Nov 1, 2019, 00:00

  • NO Specific Disease - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PAM12 GENDER DIFFERENCES IN THE DIETARY HABITS OF SECONDARY SCHOOL STUDENTS

    Nov 1, 2019, 00:00

  • PIN149 RETROSPECTIVE SURVEY FOR HEPATITIS B VIRUS REACTIVATION DURING IMMUNOSUPPRESSIVE THERAPIES FOR RHEUMATOID WITH ADMINISTRATIVE DATA

    Nov 1, 2019, 00:00

  • PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

    Nov 1, 2019, 00:00

  • PMD10 INSIGHTS INTO THE IMPACT OF POINT-OF-CARE TESTING: A SYSTEMATIC REVIEW OF HEALTH-ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PMS68 PREDICTORS OF AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS OF RHEUMATOID ARTHRITIS SEVERITY

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PIN72 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF INFLUENZA VACCINATION IN THE AUSTRIAN POPULATION

    Nov 1, 2019, 00:00

  • PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PNS416 A MODEL-BASED STANDARDISATION APPROACH TO INCREASE GENERALISABILITY OF CLAIMS DATA ANALYSES: THE EXAMPLE OF GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PRS55 PREDICTING THE RISK OF IN-HOSPITAL MORTALITY IN ADULT COMMUNITY-ACQUIRED PNEUMONIA PATIENTS WITH MACHINE LEARNING: A RETROSPECTIVE ANALYSIS OF ROUTINELY COLLECTED HEALTH DATA

    Nov 1, 2019, 00:00

  • PSU30 EQUITY OF ACCESS TO MINIMAL INVASIVE SURGERY FOR WOMEN WITH ENDOMETRIAL CANCER

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN361 A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE MAINTENANCE STRATEGIES FOR TREATMENT OF RECENTLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC) WITH BRCA MUTATION UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN29 COMPARATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT TREATMENTS IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS (RCTS)

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • NO Specific Disease - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PNS233 ECONOMIC MODEL AND METHODOLOGIES EMPLOYED IN RECENT NICE SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS

    Nov 1, 2019, 00:00

  • PMS58 HEALTH TECHNOLOGY ASSESSMENT (HTA) OF EQUISTASI FOR THE TREATMENT OF PATIENTS WITH PARKINSONIAN POST-DYSKINESIA FALLS.

    Nov 1, 2019, 00:00

  • PSU21 COST-EFFECTIVENESS OF ENDOSCOPIC SLEEVE GASTROPLASTY FOR WEIGHT LOSS

    Nov 1, 2019, 00:00

  • PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PDG6 A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (NMA) OF CRISABOROLE 2% OINTMENT FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS (AD)

    Nov 1, 2019, 00:00

  • PCN158 PATIENT BURDEN AND COSTS FOR THE TREATMENT OF MULTIPLE MYELOMA IN FINLAND IN 2009-2016, USING MULTIPLE DATA SOURCES: AN ELECTRONIC HOSPITAL DATABASE, MEDICAL CHART REVIEW, AND INTERVIEWS WITH HEALTHCARE PROFESSIONALS

    Nov 1, 2019, 00:00

  • PDB110 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM PATIENTS' PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS346 CAN META-ANALYSES HELP IN SYNTHESIZING DATA ACROSS HEALTH ECONOMIC STUDIES?

    Nov 1, 2019, 00:00

  • PMH7 LEVERAGING INNOVATIVE DIGITAL TECHNOLOGY: A NOVEL APPROACH TO SERVICE OPTIMISATION

    Nov 1, 2019, 00:00

  • PCN397 INCORPORATING RISK SCORES IN CRC SCREENING MODELS: A EXAMPLE FROM THE INCA-PHE CRC MODEL

    Nov 1, 2019, 00:00

  • PNS74 COST-EFFECTIVENESS AND RETURN-ON-INVESTMENT OF THE DYNAMIC WORK INTERVENTION

    Nov 1, 2019, 00:00

  • PRO92 AN ANALYSIS OF ORPHAN MEDICINES EXPENDITURE IN IRAN, 2018

    Nov 1, 2019, 00:00

  • PNS335 USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETY

    Nov 1, 2019, 00:00

  • PIH13 A COST-EFFECTIVENESS ANALYSIS OF ENTERAL LACTOFERRIN SUPPLEMENTATION FOR VERY PRETERM INFANTS: THE ELFIN TRIAL

    Nov 1, 2019, 00:00

  • Neurological Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PBI54 BIOSIMILAR AND ORIGINATOR INFLIXIMAB AND ETANERCEPT: INFLUENCE OF LOCAL POLICY MEASURES AND PRACTICES ON MARKET DYNAMICS IN THE UK

    Nov 1, 2019, 00:00

  • PIN39 WHEN A PROBIOTIC-BASED SANITIZING METHOD MAY HALVE HEALTHCARE-ASSOCIATED INFECTIONS AND REDUCE ASSOCIATED COSTS

    Nov 1, 2019, 00:00

  • Mental Health - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PND48 BURDEN OF MULTIPLE SCLEROSIS IN GERMANY — A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PDG23 BUDGET IMPACT ANALYSIS OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF GEP-NET AND ACROMEGALY IN THE UK

    Nov 1, 2019, 00:00

  • PCV150 DO WEATHER CHANGES AFFECT THE RISK OF STROKE? AN ANALYSIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PDG96 SURVEY ABOUT KNOWLEDGE OF NANOMEDICINES AMONG PHARMACISTS IN UKRAINE

    Nov 1, 2019, 00:00

  • PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB

    Nov 1, 2019, 00:00

  • PCV132 APPLYING EUROQOL-5D IN MIDDLE EASTERN PATIENTS WITH CARDIOVASCULAR DISEASES (CVD); A SAUDI PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN391 RISK-SHARING AGREEMENTS FOR ONCOLOGY DRUGS IN SWEDEN – THE NEW STANDARD FOR ACCESS?

    Nov 1, 2019, 00:00

  • PBI27 BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Nov 1, 2019, 00:00

  • Multiple Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN7 THE VALUE OF OBINUTUZUMAB FOR UNTREATED ADVANCED FOLLICULAR LYMPHOMA: AN ASSESSMENT BASED ON MULTICRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PSY51 PSYCHOMETRIC PERFORMANCE OF PLAQUE PSORIASIS PATIENT REPORTED OUTCOME NUMERIC RATING SCALES IN A PHASE 2B CLINICAL TRIAL

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PRS14 COST-EFECTIVENESS ANALYSIS OF AN INTERVENTION TO REDUCE THE CRITICAL HANDLING ERRORS OF FIXED-DOSE ICS/LABA COMBINATIONS IN ASTHMA PATIENTS IN SPAIN

    Nov 1, 2019, 00:00

  • PDB55 COST-EFFECTIVENESS ANALYSIS OF NONINVASIVE SCORES FOR THE SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE AMONG METABOLIC SYNDROME PATIENTS

    Nov 1, 2019, 00:00

  • Individual's Health - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN82 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN THE ITALIAN SETTING

    Nov 1, 2019, 00:00

  • PCV120 A STATISTICAL COMPARISON OF LOGISTIC REGRESSION VERSUS MACHINE LEARNING TREE-BASED CLASSIFICATION METHODS IN PREDICTING CORONARY HEART DISEASE USING REAL-WORLD PATIENT-LEVEL DATA

    Nov 1, 2019, 00:00

  • PCN275 THE GLOBAL EPIDEMIOLOGY OF PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Mental Health - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN323 CHANGE IN TREATMENT PARADIGM OF ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) IN THE ITALIAN REAL PRACTICE

    Nov 1, 2019, 00:00

  • PCV95 ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PBI53 GENE THERAPY PREPAREDNESS IN EUROPE

    Nov 1, 2019, 00:00

  • PNS312 QUANTITATIVE AND QUALITATIVE ANALYSIS OF THE AMNOG ARBITRATION BOARD DECISION FACTORS FOR THE PRICING OF NEW ACTIVE SUBSTANCES IN GERMANY

    Nov 1, 2019, 00:00

  • CC3 COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS5 RELATIVE EFFECT OF INTERVENTIONS IN ACTINIC KERATOSIS: FINDINGS FROM METHODOLOGICAL ASSESSMENT AND NETWORK META-ANALYSES

    Nov 1, 2019, 00:00

  • PIH30 CHALLENGES FACED BY PEOPLE WITH PHYSICAL DISABILITIES IN ACCESSING SEXUAL AND REPRODUCTIVE HEALTH SERVICES IN EASTERN REGION OF NEPAL

    Nov 1, 2019, 00:00

  • PSS7 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN JAPAN

    Nov 1, 2019, 00:00

  • PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • AD4 ESTIMATING THE RELIABILITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISORDER AND IDENTIFYING THE REASONS FOR NON-ADHERENCE

    Nov 1, 2019, 00:00

  • PND3 IMPACT OF SOCIAL NETWORK INTERVENTIONS ON SCHIZOPHRENIA OUTCOMES

    Nov 1, 2019, 00:00

  • PNS349 DEVELOPMENT OF PLAIN ENGLISH SUMMARIES OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REPORTS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IRELAND

    Nov 1, 2019, 00:00

  • PDB80 DIABETIC MACULAR EDEMA IN EUROPE: THE IMPACT OF PAYER POLICY ON PRESCRIBING

    Nov 1, 2019, 00:00

  • PCN495 REAL WORLD STUDIES IN ONCO-HEMATOLOGY: WHICH PARAMETER SHOULD BE USED TO MEASURE THE EFFICACY OF TREATMENTS?

    Nov 1, 2019, 00:00

  • PRS59 ADAPTION OF THE ADHERENCE BARRIERS QUESTIONNAIRE (ABQ) FOR USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PMS5 THE EFFECT OF DANCE THERAPY ON DEVELOPMENT OF MOVEMENT IN CHILDREN WITH DOWN SYNDROME

    Nov 1, 2019, 00:00

  • PMH42 TARGETED LITERATURE REVIEW (TLR) OF THE ECONOMIC BURDEN OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS)

    Nov 1, 2019, 00:00

  • PCN14 MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

    Nov 1, 2019, 00:00

  • PMH68 IMPLEMENTING AND INTERPRETING A PROPOSED NEW MEASURE FOR HEDIS® 2020: PHARMACOTHERAPY FOR OPIOID USE DISORDER (OUD)

    Nov 1, 2019, 00:00

  • PNS381 THE RISE OF THE SOCIAL MEDIA MACHINE: A REVIEW OF PATIENT-CENTERED RESEARCH UTILIZING SOCIAL MEDIA RESEARCH METHODS PRESENTED AT ISPOR (2010 -2018)

    Nov 1, 2019, 00:00

  • PNS297 CLINICAL AND KEY OPINION LEADERS VALIDATION IN HEALTH ECONOMICS MODEL AND COMPARATIVE EFFECTIVENESS: A GUIDE FOR NON-EXPERT AUDIENCE

    Nov 1, 2019, 00:00

  • PDB70 CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY TREATED WITH BASAL INSULIN THERAPY: A POPULATION-BASED UK STUDY

    Nov 1, 2019, 00:00

  • Neurological Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PNS152 WILLINGNESS TO PAY FOR SOCIAL HEALTH INSURANCE AND RELATED FACTORS AMONG POPULATION IN YOGYAKARTA PROVINCE, INDONESIA

    Nov 1, 2019, 00:00

  • PNS292 BUDGET IMPACT OF SOFTWARE SUPPORTING SAFE, EFFECTIVE AND EFFICIENT WORKING OF NHS ACUTE CARE PROVIDERS: ACTUAL BUDGET IMPACT FOR IMPLEMENTATION SITE AND LOST OPPORTUNITY SAVING AND PROJECTED BUDGET IMPACT POTENTIAL FOR OTHER SITES

    Nov 1, 2019, 00:00

  • PCN488 A SYSTEMATIC LITERATURE REVIEW OF STUDIES REPORTING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH METASTATIC PANCREATIC CANCER BEFORE OR AFTER TREATMENT

    Nov 1, 2019, 00:00

  • PMU119 WHAT ARE THE KEY CHALLENGES ENCOUNTERED IN THE DESIGN, CONDUCT AND ASSESSMENT OF PRAGMATIC TRIALS AND HOW ARE THEY ADDRESSED?

    Nov 1, 2019, 00:00

  • PMD34 FRENCH COVERAGE WITH EVIDENCE DEVELOPMENT (CED) SCHEME FOR INNOVATIVE MEDICAL DEVICES: AN OVERVIEW SINCE ITS REDESIGN IN 2015

    Nov 1, 2019, 00:00

  • Infectious Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PBI44 REAL-WORLD EVIDENCE IN GENE THERAPIES: RECOMMENDATIONS VERSUS REALITY

    Nov 1, 2019, 00:00

  • PMU38 COSTS-EFFECTIVITY, HEALTH ECONOMIC EVALUATION, SYSTEMATIC REVIEW AND METANALYSIS OF BARIATRIC SURGERY IN REDUCING OBESITY RELATED DISEASES, MORTALITY, DEPRESSION AND CANCER

    Nov 1, 2019, 00:00

  • PUK32 PATIENT INSIGHTS FOR IMMUNOGLOBULIN A NEPHROPATHY (IGAN) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00

  • PDB65 PRETRIAL MODELLING METHODS TO JUSTIFY AND INFORM THE DESIGN OF LARGE RCTS - EXPECTED VALUE OF SAMPLE INFORMATION FOR THE DAFNEPLUS DIABETES EDUCATION CLUSTER RCT

    Nov 1, 2019, 00:00

  • PNS172 TRENDS IN PRESCRIPTION MONITORING PROGRAM PATIENT QUERIES AND DELEGATE ACCESS

    Nov 1, 2019, 00:00

  • PNS191 IMPLEMENTATION OF A NEW MODEL OF THE NURSING CARE MANAGEMENT IN THE REPUBLIC OF KAZAKHSTAN: POLICY BRIEF

    Nov 1, 2019, 00:00

  • PNS398 THE ASSOCIATION BETWEEN EHEALTH-LITERACY, SHARED DECISION-MAKING AND HEALTH RISK BEHAVIOURS IN AN ONLINE SAMPLE OF THE HUNGARIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PUK27 THE ECONOMIC IMPACT OF DIGITAL HEALTH INTERVENTIONS IN THE MANAGEMENT OF TYPE 2 DIABETES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Cancer - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PIH43 CAN USING POINT OF CARE BLOOD TESTS HELP INFORM DECISION MAKING FOR PATIENTS WITH ACUTE FRAILTY SYNDROME? A BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PCN233 COST EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE VS BENDAMUSTINE ALONE FOR PATIENTS WHO DID NOT RESPOND OR PROGRESSED DURING OR AFTER RITUXIMAB OR A RITUXIMAB CONTAINING REGIMENT IN TURKEY

    Nov 1, 2019, 00:00

  • PSY26 UNMET MEDICAL NEED OF PRURIGO NODULARIS

    Nov 1, 2019, 00:00

  • PNS252 DO MARKET WITHDRAWALS IMPACT PATIENT ACCESS TO TREATMENT IN GERMANY?

    Nov 1, 2019, 00:00

  • PRO94 EXPLORING POTENTIAL CLINICAL BENEFITS AND COST SAVINGS FROM IMPLEMENTING A STANDARDIZED DIGITAL REFERRAL PROCESS FOR DIAGNOSIS AND MANAGEMENT OF RARE DISEASES IN SPAIN: A CASE EXAMPLE FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

    Nov 1, 2019, 00:00

  • PBI77 PAYING FOR CURES: AN ANALYSIS OF INNOVATIVE ACCESS AGREEMENTS FOR LICENSED GENE THERAPIES

    Nov 1, 2019, 00:00

  • Individual's Health - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs [Editor's Choice]

    Nov 1, 2019, 00:00

  • PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)

    Nov 1, 2019, 00:00

  • PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PRO84 REGULATORY AND MARKET ACCESS LANDSCAPE FOR CYSTIC FIBROSIS

    Nov 1, 2019, 00:00

  • PIN150 ANALYSIS OF TREATMENT SEQUENCES FROM THE FRENCH NATIONAL SNIIRAM DATABASE: CASE STUDY OF INCIDENT PEOPLE LIVING WITH HIV IN 2013

    Nov 1, 2019, 00:00

  • PCN298 IMPROVED DRG-BASED REIMBURSEMENT OF ANTINEOPLASTIC PHARMACOTHERAPY AT RUSSIAN HOSPITALS

    Nov 1, 2019, 00:00

  • PNS153 MOVING TOWARD UNIVERSAL HEALTH COVERAGE IN JORDAN

    Nov 1, 2019, 00:00

  • PRO157 PREDICTING HEALTH UTILITIES FROM PATIENT-REPORTED OUTCOME MEASURES (PROMS) IN RARE DISEASES: A SYSTEMATIC REVIEW OF MAPPING STUDIES

    Nov 1, 2019, 00:00

  • PCV18 THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • Injury Trauma - Medical Technologies

    Nov 1, 2019, 00:00

  • PMD12 UNDERSTANDING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN PUNE, INDIA

    Nov 1, 2019, 00:00

  • Stroke Warning Information and Faster Treatment (SWIFT): Cost-Effectiveness of a Stroke Preparedness Intervention

    Nov 1, 2019, 00:00

  • PNS270 ASSESSING THE PUBLIC HEALTH BENEFIT OF A MEDICINE: AN ANALYSIS OF THE CRITERIA APPRAISED BY THE FRENCH HTA BODY SINCE THE PUBLICATION OF ITS UPDATED MISSION STATEMENT OF SEPTEMBER 2018

    Nov 1, 2019, 00:00

  • PCN24 TYROSINE KINASE INHIBITORS: REAL WORLD EVIDENCE ABOUT HEALTH OUTCOMES IN A MIDDLE INCOME COUNTRY

    Nov 1, 2019, 00:00

  • PIH23 ECONOMIC BURDEN OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT) PATIENT IN MALAYSIA: A SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU90 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)

    Nov 1, 2019, 00:00

  • PMU41 THE ASSOCIATION BETWEEN MULTIMORBIDITY AND PERCEIVED WORKING CONDITIONS IN EUROPE

    Nov 1, 2019, 00:00

  • PCN113 COST-MINIMISATION AND FIVE-YEAR BUDGET IMPACT ANALYSIS FOR MVASI® (BEVACIZUMAB BIOSIMILAR) IN ITALY

    Nov 1, 2019, 00:00

  • PCN94 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT DRUGS FOR FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PDB31 TRENDS IN THE USES OF ANTI-OSTEOPOROTIC DRUGS IN TAIWAN FROM 2012 TO 2018

    Nov 1, 2019, 00:00

  • PNS76 A BAYESIAN PARAMETRIC APPROACH TO HANDLE MISSING LONGITUDINAL OUTCOME DATA IN TRIAL-BASED HEALTH ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PCN197 BUDGET IMPACT OF LUNG CANCER SCREENING WITH LOW-DOSE COMPUTERIZED TOMOGRAPHY FOR SMOKING GROUPS

    Nov 1, 2019, 00:00

  • PMU136 PSYCHOMETRIC PROPERTIES OF MALE SEXUAL HEALTH QUESTIONNAIRE (MSHQ), IN HIV AND HCV PATIENTS

    Nov 1, 2019, 00:00

  • PND109 PATIENT PREFERENCE FOR DOSING REGIMEN AND PERCEPTION OF DOSING FLEXIBILITY WITH FREMANEZUMAB FOR CHRONIC OR EPISODIC MIGRAINE: RESULTS FROM A WEB-BASED, PATIENT SURVEY FOLLOWING COMPLETION OF A 1-YEAR EXTENSION STUDY

    Nov 1, 2019, 00:00

  • PNS125 SHOULD DRUG PRICES DIFFER BY INDICATION? RESULTS OF A CONSULTATION

    Nov 1, 2019, 00:00

  • PSY50 PATIENT PREFERENCES FOR PATIENT-CENTERED HEALTHCARE IN THE TREATMENT OF HEMOPHILIA: A BEST-WORST SCALING CASE 3

    Nov 1, 2019, 00:00

  • PIN128 BUDGET IMPACT ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00

  • PMU28 CAVEATS IN COST-EFFECTIVENESS ANALYSIS OF REMOTE PATIENT MONITORING: IMPACT OF END-OF-LIFE ADJUSTMENT OF QALYS ON DECISION MAKING METRICS

    Nov 1, 2019, 00:00

  • PNS242 BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIA

    Nov 1, 2019, 00:00

  • PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS

    Nov 1, 2019, 00:00

  • IN2 IMPACT OF TESTING RAPID INITIATION ON HIV INCIDENCE IN FRANCE: RESULTS OF A TRANSMISSION MODEL

    Nov 1, 2019, 00:00

  • PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PCN290 IMPLEMENTATION OF COMBINATION THERAPY PRICING RULES IN ONCOLOGY: LESSONS FROM MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PSU6 ECONOMIC IMPACT OF A VALIDATED INTRAOPERATIVE BLEEDING SCALE: A RETROSPECTIVE MULTICENTER REVIEW FROM THE US PROSCPECTIVE

    Nov 1, 2019, 00:00

  • PRO134 HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY

    Nov 1, 2019, 00:00

  • PCN446 A CASE STUDY OF BREAST CANCER TREATMENT DEMONSTRATING THE IMPACT OF TIME DEPENDENT TRANSITION PROBABILITY ADJUSTMENTS ON COMPARATIVE COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PNS317 FAILURE OR EFFECT: ATTRIBUTE FRAMING IN A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2019, 00:00

  • PCN526 PHYSICIAN ACCEPTANCE OF REAL-WORLD EVIDENCE IN DRUG APPROVAL AND LABELING

    Nov 1, 2019, 00:00

  • PCN459 DEVELOPMENT OF A PATIENT-CENTERED CONCEPTUAL MODEL DESCRIBING THE IMPACT OF LIVING WITH HEPATOCELLULAR CARCINOMA

    Nov 1, 2019, 00:00

  • PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Nov 1, 2019, 00:00

  • PIN38 THE COST OF STIGMA ASSOCIATED WITH HIV: A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA

    Nov 1, 2019, 00:00

  • PCN507 CAN TRANSFERABILITY OF CLINICAL TRIALS POPULATION TO REAL WORLD SETTING BE ASSESSED USING FRENCH NATIONAL HEALTHCARE DATABASE? A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PDB17 HEALTH ECONOMIC EFFECTS OF THE UPDATED FOOT ULCER SUBMODEL IN THE IQVIA CORE DIABETES MODEL

    Nov 1, 2019, 00:00

  • PNS399 DEVELOPMENT OF POPULATION TARIFFS FOR THE CARER-QOL-7D INSTRUMENT FOR HUNGARY, POLAND AND SLOVENIA: A DISCRETE CHOICE EXPERIMENT STUDY TO MEASURE THE BURDEN OF INFORMAL CAREGIVING

    Nov 1, 2019, 00:00

  • PNS386 PATIENT PREFERENCES IN THE MEDICAL PRODUCT LIFECYCLE: INITIAL RESULTS FROM THE IMI PREFER PUBLIC-PRIVATE PROJECT

    Nov 1, 2019, 00:00

  • PAM5 A SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF INTERVENTIONS WITH A PERSONALIZED NUTRITION COMPONENT IN ADULTS

    Nov 1, 2019, 00:00

  • PNS28 ADVANCING VALUE ASSESSMENTS: HOW CAN A PARADIGM OF VALUE MEASUREMENT BEYOND QALY BE ENHANCED TO HOLISTICALLY CAPTURE WHAT TRULY MATTERS TO PATIENTS AND PAYERS?

    Nov 1, 2019, 00:00

  • PND121 ANTIPSYCHOTICS UTILIZATION AND DIRECT MEDICAL COSTS ASSOCIATED WITH SCHIZOPHRENIA IN CHINESE PATIENTS

    Nov 1, 2019, 00:00

  • PCN242 REDEFINING VALUE IN ONCOLOGY: APPLICATION OF MIXTURE CURE MODELS FOR ECONOMIC ANALYSES OF NOVEL THERAPIES FOR SMALL CELL LUNG CANCER (SCLC)

    Nov 1, 2019, 00:00

  • PSU3 ALTERATIONS IN PATIENT WEIGHT AND CLINICAL FACTORS FOLLOWING GASTRIC BYPASS SURGERY

    Nov 1, 2019, 00:00

  • PBI83 GOLIMUMAB IMPROVES QUALITY OF LIFE AND OTHER PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN REAL-WORLD CONDITIONS

    Nov 1, 2019, 00:00

  • PRS11 EVIDENCE SYNTHESIS IN PULMONARY ARTERIAL HYPERTENSION: A CRITICAL APPRAISAL

    Nov 1, 2019, 00:00

  • PCV59 HOSPITAL LENGTH OF STAY AMONG VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH APIXABAN AND WARFARIN IN ENGLAND

    Nov 1, 2019, 00:00

  • PCN154 INCORPORATING THE VALUE HEALTHY INDIVIDUALS PLACE ON GENEROUS INSURANCE COVERAGE OF SEVERE DISEASES: A STATED PREFERENCE SURVEY OF ADULT COHORTS WITH AND AT-RISK FOR LUNG CANCER

    Nov 1, 2019, 00:00

  • PBI17 BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILAR RITUXIMAB AND TRASTUZUMAB COMPARED TO INTRAVENOUS AND SUBCUTANEOUS ORIGINATORS IN FRANCE, GERMANY, ITALY, SPAIN, AND THE UK

    Nov 1, 2019, 00:00

  • PCN45 PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) — A NETWORK META-ANALYSIS (NMA)

    Nov 1, 2019, 00:00

  • PCN360 SURROGATE ENDPOINT VALIDATION STUDIES SUBMITTED TO THE GERMAN HEALTH TECHNOLOGY ASSESSMENT AUTHORITY, THE FEDERAL JOINT COMMITTEE (G-BA). CASE STUDIES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PDB53 BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS TYPE II IN RUSSIA

    Nov 1, 2019, 00:00

  • PIN58 ARE PUBLISHED HEALTH ECONOMIC MODELS FOR CHRONIC HEPATITIS B APPROPRIATELY CAPTURING THE BENEFITS OF HBSAG LOSS?

    Nov 1, 2019, 00:00

  • PIH22 ESTIMATING THE PRODUCTIVITY BURDEN OF PEDIATRIC PNEUMOCOCCAL DISEASE IN THAILAND

    Nov 1, 2019, 00:00

  • Individual's Health - Economic Evaluation

    Nov 1, 2019, 00:00

  • PDG58 THE IMPACT OF ECONOMIC REGULATION ON EXPANSIVE DRUG LIST IN FRANCE BETWEEN 2008 AND 2018

    Nov 1, 2019, 00:00

  • PCN251 THE INCIDENCE OF SOFT TISSUE SARCOMA OVER THE NEXT TWO DECADES (2018-2040)

    Nov 1, 2019, 00:00

  • PCV153 HOW COSTLY IS POOR ADHERENCE TO PHARMACOLOGICAL TREATMENTS FOR CARDIOVASCULAR DISEASE? A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PIH3 VARIATIONS IN DURATION OF MECHANICAL VENTILATION IN VERY LOW BIRTH WEIGHT INFANTS IN JAPAN

    Nov 1, 2019, 00:00

  • PCN311 OPTIMAL BREAST CANCER SCREENING POLICY STRATIFYING BY BREAST DENSITY

    Nov 1, 2019, 00:00

  • PBI58 RESISTANCE TO OR SUPPORT OF BIOSIMILARS' MARKET PENETRATION? A SYSTEMATIC REVIEW OF EUROPEAN STAKEHOLDERS' BEHAVIOURS

    Nov 1, 2019, 00:00

  • PNS79 DETERMINING THE BASELINE STRATEGY IN A COST-EFFECTIVENESS ANALYSIS WITH TREATMENT SEQUENCES

    Nov 1, 2019, 00:00

  • PRO91 UTILITY OF REAL WORLD EVIDENCE DATA TO SUPPORT MARKET ACCESS OF RARE ONCOLOGY INDICATIONS IN EU5

    Nov 1, 2019, 00:00

  • Multiple Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PIH33 FREQUENCY AND NATURE OF INPATIENT TREATMENT OF MULTIPLE OSTEOCHONDROMA (MO) IN GERMANY FROM 2005 TO 2016

    Nov 1, 2019, 00:00

  • A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer’s Disease in Thailand

    Oct 1, 2019, 00:00

  • External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data

    Oct 1, 2019, 00:00

  • A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management [Editor's Choice]

    Oct 1, 2019, 00:00

  • Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier

    Oct 1, 2019, 00:00

  • A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist–Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH)

    Oct 1, 2019, 00:00

  • Risk of Dependency: A Challenge for Health and Social Care Planning--Observational Stroke Cohort

    Oct 1, 2019, 00:00

  • Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma

    Oct 1, 2019, 00:00

  • Table of Contents

    Oct 1, 2019, 00:00

  • A Comparison of National Guidelines for Network Meta-Analysis

    Oct 1, 2019, 00:00

  • Estimators Used in Multisite Healthcare Costing Studies in Low- and Middle-Income Countries: A Systematic Review and Simulation Study

    Oct 1, 2019, 00:00

  • On the Optimization of Bayesian D-Efficient Discrete Choice Experiment Designs for the Estimation of QALY Tariffs That Are Corrected for Nonlinear Time Preferences [Editor's Choice]

    Oct 1, 2019, 00:00

  • Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice

    Oct 1, 2019, 00:00

  • Choosing Video Instead of In-Clinic Consultations in Primary Care in Israel: Discrete Choice Experiment Among Key Stakeholders—Patients, Primary Care Physicians, and Policy Makers

    Oct 1, 2019, 00:00

  • Copyright/Subscription

    Oct 1, 2019, 00:00

  • Implementing Patient-Reported Outcome Measures in Clinical Breast Cancer Care: A Systematic Review [Editor's Choice]

    Oct 1, 2019, 00:00

  • Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities

    Oct 1, 2019, 00:00

  • Editorial Board

    Sep 26, 2019, 08:53

  • Copyright/Subscription

    Sep 9, 2019, 08:11

  • Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time

    Sep 1, 2019, 00:00

  • A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions

    Sep 1, 2019, 00:00

  • Value of the Rare Disease Registry of the Italian Region Friuli Venezia Giulia

    Sep 1, 2019, 00:00

  • Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms

    Sep 1, 2019, 00:00

  • Adjusting for Inflation and Currency Changes Within Health Economic Studies

    Sep 1, 2019, 00:00

  • Evaluation of the Association Between Health State Utilities and Obesity in Sub-Saharan Africa: Evidence From World Health Organization Study on Global AGEing and Adult Health Wave 2

    Sep 1, 2019, 00:00

  • Barriers and Facilitators to Model Replication Within Health Economics [Editor's Choice]

    Sep 1, 2019, 00:00

  • Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer

    Sep 1, 2019, 00:00

  • Are Healthcare Choices Predictable? The Impact of Discrete Choice Experiment Designs and Models [Editor's Choice]

    Sep 1, 2019, 00:00

  • Editorial Board

    Sep 1, 2019, 00:00

  • Development and Psychometric Validation of an Instrument to Identify Barriers to Self-Care Among Spanish Patients With Type 2 Diabetes on the Basis of Theory of Planned Behavior

    Sep 1, 2019, 00:00

  • Extrapolating Survival Data Using Historical Trial–Based a Priori Distributions

    Sep 1, 2019, 00:00

  • Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy

    Sep 1, 2019, 00:00

  • Table of Contents

    Sep 1, 2019, 00:00

  • Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012

    Sep 1, 2019, 00:00

  • As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time? [Editor's Choice]

    Sep 1, 2019, 00:00

  • Editorial Board

    Aug 16, 2019, 09:04

  • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre

    Aug 1, 2019, 00:00

  • Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure

    Aug 1, 2019, 00:00

  • When Opportunity Knocks, What Does It Say?

    Aug 1, 2019, 00:00

  • Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications

    Aug 1, 2019, 00:00

  • Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis

    Aug 1, 2019, 00:00

  • PROM Validation Using Paper-Based or Online Surveys: Data Collection Methods Affect the Sociodemographic and Health Profile of the Sample

    Aug 1, 2019, 00:00

  • Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration [Editor's Choice]

    Aug 1, 2019, 00:00

  • United States Valuation of EQ-5D-5L Health States Using an International Protocol

    Aug 1, 2019, 00:00

  • A Scoping Review of Investment Cases for Vaccines and Immunization Programs

    Aug 1, 2019, 00:00

  • Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment [Editor's Choice]

    Aug 1, 2019, 00:00

  • Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration–Approved Gene Therapy and Implications for Future One-Time Therapies

    Aug 1, 2019, 00:00

  • An Ethical Analysis of Coverage With Evidence Development [Editor's Choice]

    Aug 1, 2019, 00:00

  • Table of Contents

    Aug 1, 2019, 00:00

  • Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model

    Aug 1, 2019, 00:00

  • Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data

    Aug 1, 2019, 00:00

  • Author Reply

    Aug 1, 2019, 00:00

  • Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L

    Aug 1, 2019, 00:00

  • Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015 [Editor's Choice]

    Aug 1, 2019, 00:00

  • Copyright/Subscription

    Aug 1, 2019, 00:00

  • Editorial Board

    Jul 2, 2019, 09:19

  • Time-Driven Activity-Based Costing in Urologic Surgery Cycles of Care

    Jul 1, 2019, 00:00

  • Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

    Jul 1, 2019, 00:00

  • Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study

    Jul 1, 2019, 00:00

  • How Prevalent Are Implausible EQ-5D-5L Health States and How Do They Affect Valuation? A Study Combining Quantitative and Qualitative Evidence

    Jul 1, 2019, 00:00

  • Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States

    Jul 1, 2019, 00:00

  • Parent Proxy Discrepancy Groups of Quality of Life in Childhood Epilepsy

    Jul 1, 2019, 00:00

  • The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory

    Jul 1, 2019, 00:00

  • How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma

    Jul 1, 2019, 00:00

  • Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory? [Editor's Choice]

    Jul 1, 2019, 00:00

  • Machine Learning for Health Services Researchers [Editor's Choice]

    Jul 1, 2019, 00:00

  • Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers

    Jul 1, 2019, 00:00

  • Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?

    Jul 1, 2019, 00:00

  • Copyright/Subscription

    Jul 1, 2019, 00:00

  • ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products

    Jul 1, 2019, 00:00

  • A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis

    Jul 1, 2019, 00:00

  • Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2

    Jul 1, 2019, 00:00

  • Table of Contents

    Jul 1, 2019, 00:00

  • Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

    Jun 1, 2019, 00:00

  • Valuing Health Status in the First Year of Life: The Infant Health-Related Quality of Life Instrument

    Jun 1, 2019, 00:00

  • New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare—An Introduction

    Jun 1, 2019, 00:00

  • Table of Contents

    Jun 1, 2019, 00:00

  • Current Policy and Practice for Value-Based Pricing

    Jun 1, 2019, 00:00

  • A Beginner's Guide to Understanding Curative Therapies

    Jun 1, 2019, 00:00

  • Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice

    Jun 1, 2019, 00:00

  • Current Value Frameworks—What's New?

    Jun 1, 2019, 00:00

  • Meaningful and Measurable Health Domains in Huntington’s Disease: Large-Scale Validation of the Huntington’s Disease Health-Related Quality of Life Questionnaire Across Severity Stages

    Jun 1, 2019, 00:00

  • Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions

    Jun 1, 2019, 00:00

  • Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?

    Jun 1, 2019, 00:00

  • Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy [Editor's Choice]

    Jun 1, 2019, 00:00

  • Patient Preferences for Endometriosis Pain Treatments in the United States

    Jun 1, 2019, 00:00

  • Development and Validation of the MiPrep Survey: An Instrument Assessing Patients' Perceived Preparation for Medical Interventions Including Medical Imaging, Radiotherapy, and Surgery

    Jun 1, 2019, 00:00

  • A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

    Jun 1, 2019, 00:00

  • Are Global Health Systems Ready for Transformative Therapies?

    Jun 1, 2019, 00:00

  • Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System [Editor's Choice]

    Jun 1, 2019, 00:00

  • Specific Value Assessment Considerations

    Jun 1, 2019, 00:00

  • Copyright/Subscription

    Jun 1, 2019, 00:00

  • Editorial Board

    Jun 1, 2019, 00:00

  • New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options? [Editor's Choice]

    Jun 1, 2019, 00:00

  • How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom?

    Jun 1, 2019, 00:00

  • Novel Approaches to Value Assessment Beyond the Cost-Effectiveness Framework

    Jun 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46 (current)
  • 47
  • 48
  • 49
  • 50
  • »